Updated: Oct 9, 2022
Photo Credits: By holdentrils on Pixabay
What Is This Miracle Treatment?
It is official, there is finally some good news about a drug that may alleviate early-stage Alzheimer's disease. Companies like Biogen and Eisai have been working effortlessly to conduct research on a treatment for the disease. This week, they have announced in a clinical trial that lecanemab has reduced cognitive decline by 27% in early stage Alzheimers patients.
What is Lecanemab?
Lecanemab(BAN 2401) is a monoclonal antibody treatment that will help prevent the production of amyloid beta, the protein that is found in the brains of Alzheimers patients.
Researchers are hopeful that the treatment will be available to the public in late November. However, it may still be too early to be sure for the exact date. Additional research and data is being produced to ensure that lecanemab is the right solution to combating early Alzheimers.
The release of this treatment will be a tremendous milestone as 6 million Americans have Alzheimer's and the number is expected to double in the next few decades. Many are banking on the revolutionary effects of the drug through the year. If lecanemab is released, we can see relief in people who have loved ones with the disease.
Voyage MIA Interview: http://voyagemia.com/interview/daily-inspiration-meet-diondre-mompoint/
ShoutoutLA Interview: https://shoutoutla.com/meet-diondre-m...